GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NeuroSense Therapeutics
NeuroSense is an Israeli biotech company developing drugs for the treatment of ALS and other neurodegenerative diseases. Its stock price is driven by news of clinical trials and hopes for a breakthrough in this complex field.
Share prices of companies in the market segment - Neuro
NeuroSense Therapeutics is an Israeli biopharmaceutical company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS). We've categorized it under "Neurology." The chart below reflects how investors assess the risks and prospects in this complex field.
Broad Market Index - GURU.Markets
NeuroSense Therapeutics is an Israeli biopharmaceutical company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market.
Change in the price of a company, segment, and market as a whole per day
NRSN - Daily change in the company's share price NeuroSense Therapeutics
For NeuroSense Therapeutics Ltd., which develops drugs for ALS, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
NeuroSense Therapeutics Ltd. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with the performance of NRSN, which focuses on treating neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
NeuroSense Therapeutics is an Israeli biotech company developing drugs to treat ALS. Its shares are driven by news of clinical trials. This high volatility, driven by hopes, is a significant component of the overall "noise" and stock market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NeuroSense Therapeutics
NeuroSense Therapeutics' year-end performance is a story about the development of a drug for the treatment of amyotrophic lateral sclerosis (ALS). Its market capitalization over the next 12 months depends entirely on clinical trial data. The success of its combination drug could offer new hope for patients with this devastating neurodegenerative disease.
Annual dynamics of market capitalization of the market segment - Neuro
NeuroSense, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NeuroSense is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NeuroSense Therapeutics
NeuroSense is a biotech company targeting neurodegenerative diseases such as ALS. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its combination therapies are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Neuro
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This is one of the most complex areas in medicine. The dynamics of the biotech sector reflect the hopes for breakthroughs. NeuroSense's story is a risky bet that its scientific approach can slow or stop the progression of these devastating diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company developing a treatment for amyotrophic lateral sclerosis (ALS). The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to understand how its potential to treat this deadly disease has impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NeuroSense Therapeutics
NeuroSense Therapeutics is a biotech company developing treatments for neurodegenerative diseases such as ALS. Its weekly stock price is highly volatile and depends on news about clinical trials, where the stakes are high due to the complexity of these diseases.
Weekly dynamics of market capitalization of the market segment - Neuro
NeuroSense Therapeutics is a biotech company developing treatments for neurodegenerative diseases such as ALS. Its weekly stock price is highly volatile and depends on news about clinical trials, where the stakes are high due to the complexity of these diseases.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NeuroSense, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
NRSN - Market capitalization of the company NeuroSense Therapeutics
The NeuroSense market capitalization chart tells the story of an Israeli biotech company developing a drug to treat amyotrophic lateral sclerosis (ALS). Its volatile chart reflects investor hopes for a breakthrough in the treatment of this deadly disease.
NRSN - Share of the company's market capitalization NeuroSense Therapeutics within the market segment - Neuro
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of amyotrophic lateral sclerosis (ALS). Its share of its segment's market capitalization reflects investor expectations for its development. The chart below shows the high volatility associated with clinical trial news.
Market capitalization of the market segment - Neuro
NeuroSense Therapeutics is developing a combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). The chart below shows the overall market capitalization of the neuroscience sector. It reflects the enormous need for treatment for this devastating disease, for which there are currently no effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the fight against ALS (amyotrophic lateral sclerosis). NeuroSense Therapeutics is developing a combination drug to treat this deadly neurodegenerative disease. Its volatile line reflects the hopes of patients and investors for progress in this complex field.
Book value capitalization of the company, segment and market as a whole
NRSN - Book value capitalization of the company NeuroSense Therapeutics
NeuroSense's foundation is its intellectual property for a combination drug for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. This represents focused scientific capital. The chart below shows how the Israeli biotech company manages its budget for clinical trials of its innovative therapy.
NRSN - Share of the company's book capitalization NeuroSense Therapeutics within the market segment - Neuro
NeuroSense Therapeutics is a biotech company developing treatments for ALS and other neurodegenerative diseases. Its assets are intellectual property. The chart shows the minimum share of physical assets.
Market segment balance sheet capitalization - Neuro
The development of CNS drugs, as the BCap_Ges chart shows, is a science-intensive endeavor. NeuroSense Therapeutics operates in this environment, where capital is invested in clinical research rather than manufacturing. Its assets are intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
NeuroSense's book value represents capital allocated for clinical trials of a drug for the treatment of ALS. It reflects the financial foundation that allows the company to work toward developing a tangible drug capable of slowing the progression of this fatal neurodegenerative disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NeuroSense Therapeutics
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases like ALS. This is one of the most complex areas in biotech. Its market cap is a pure bet on scientific success. The MvsBCap chart will reflect all the hopes and disappointments associated with finding a cure for these dreadful diseases.
Market to book capitalization ratio in a market segment - Neuro
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases such as ALS. Its value is entirely dependent on the success of its clinical trials. The chart reflects investor hopes for a breakthrough in this complex area of medicine.
Market to book capitalization ratio for the market as a whole
NeuroSense Therapeutics is developing combination therapies for ALS and other neurodegenerative diseases. The company's valuation is a bet on the success of its scientific approach to treating extremely complex diseases. The chart shows how investors value the science and hope that have not yet translated into revenue.
Debts of the company, segment and market as a whole
NRSN - Company debts NeuroSense Therapeutics
NeuroSense, a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as ALS, is devoting all of its capital to R&D. This chart shows how the company is funding its complex and expensive clinical trials in hopes of finding a cure for one of the most devastating diseases.
Market segment debts - Neuro
NeuroSense Therapeutics is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases such as ALS. This is one of the most complex areas in medicine. The chart shows how the company funds its extremely complex and expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NeuroSense Therapeutics
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases such as ALS. This chart reflects its high reliance on debt to finance extremely expensive and time-consuming clinical trials. Success can yield enormous returns, but failure means the company will be unable to service its debt.
Market segment debt to market segment book capitalization - Neuro
NeuroSense Therapeutics is a clinical-stage company developing drugs to treat neurodegenerative diseases such as ALS. The chart shows the sector's debt load, helping to understand how the company finances its long-term, high-risk research in one of the most complex areas of medicine.
Debt to book value of all companies in the market
NeuroSense Therapeutics is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases such as ALS. This chart, which shows the company's financial climate, is critical. Access to long-term investments required to conduct complex and expensive clinical trials is directly dependent on market stability.
P/E of the company, segment and market as a whole
P/E - NeuroSense Therapeutics
This chart of NeuroSense Therapeutics, a company developing a treatment for ALS, shows the high but risky expectations of investors. The trend reflects faith in a potential scientific breakthrough in treating this deadly disease, where the success of a single drug could lead to a multibillion-dollar business.
P/E of the market segment - Neuro
This chart reflects the average P/E for the biopharmaceutical industry in which NeuroSense is developing. The sector's very high average valuation reflects hopes for scientific breakthroughs. The chart illustrates this general backdrop against which NeuroSense's potential for treating ALS is assessed.
P/E of the market as a whole
NeuroSense Therapeutics is a clinical-stage biotech company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. This chart illustrates risk appetite in biotech. It helps understand how the market views NeuroSense's chances of success in this challenging area of medicine, where many have failed.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NeuroSense Therapeutics
NeuroSense Therapeutics is an Israeli biotech company developing a drug for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. This chart demonstrates analysts' confidence that clinical trials will be successful and that the drug will become a new treatment option for these serious illnesses.
%20P%2FE%20NeuroSense%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NeuroSense-Therapeutics&v=1772612878043 "Chart of the company's future (projected) P/E NeuroSense Therapeutics")
Future (projected) P/E of the market segment - Neuro
NeuroSense Therapeutics is a clinical-stage company developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart displays its future profitability expectations, allowing us to assess how highly the market values its scientific approach to treating these devastating diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772612878084 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
NeuroSense Therapeutics is a clinical-stage company developing drugs to treat neurodegenerative diseases such as ALS. Its valuation reflects the hope for a scientific breakthrough. This chart, reflecting investors' risk appetite, is critically important. Market optimism allows NeuroSense to raise capital to continue its vital research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612878101 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NeuroSense Therapeutics
NeuroSense Therapeutics is an Israeli biotech company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its funding comes from investments in clinical trials. This chart shows how much money is being invested in the fight against some of humanity's most devastating diseases.
Profit of companies in the market segment - Neuro
NeuroSense Therapeutics is a clinical-stage biotech company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. This graph reflects the high risk and potential of the neuroscience sector, where the development of an effective therapy for such diseases would be a major breakthrough and generate billions in revenue.
Overall market profit
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases such as ALS. This is an area with a huge unmet need. The overall market situation, which is indirectly reflected in this graph, affects the availability of capital to fund long and risky clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NeuroSense Therapeutics
NeuroSense Therapeutics is developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS), a rare and fatal neurodegenerative disease. This chart reflects analyst expectations, which are essentially an estimate of the likelihood of clinical trial success and the drug's commercial potential.
%20profit%20of%20the%20company%20NeuroSense%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NeuroSense-Therapeutics&v=1772612878190 "Graph of future (projected) profit of the company NeuroSense Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
NeuroSense Therapeutics is a clinical-stage biotech company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. This chart shows profitability projections for the biotech sector, reflecting the high hopes for the development of effective therapies for these devastating and currently incurable diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772612878204 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
NeuroSense Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as ALS. Its development depends on trial results and its ability to raise capital. This graph, reflecting market sentiment, influences investor willingness to fund long-term, high-risk medical projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612878209 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NeuroSense Therapeutics
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases. This chart shows its estimated scientific potential. The high valuation and minimal sales reflect investors' hopes for a breakthrough in the treatment of complex diseases like ALS.
P/S market segment - Neuro
NeuroSense Therapeutics Ltd. is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows the average revenue estimate in the biotech sector. It helps understand the premium investors are placing on the potential of NeuroSense's drugs to treat serious diseases.
P/S of the market as a whole
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS), a rare and fatal disease. Their goal is to slow the progression of the disease. This chart provides a general revenue metric that underscores the high expectations investors have for rare disease treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NeuroSense Therapeutics
NeuroSense Therapeutics is an Israeli biotech company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS). This chart reflects investor expectations for a breakthrough in the treatment of this rare and fatal disease. The valuation is entirely dependent on the results of clinical trials.
%20P%2FS%20NeuroSense%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NeuroSense-Therapeutics&v=1772612878319 "The graph of the company's future (projected) P/S NeuroSense Therapeutics")
Future (projected) P/S of the market segment - Neuro
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS). This chart shows how the market perceives its potential to treat this severe neurological disease.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772612878381 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
NeuroSense Therapeutics is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases such as ALS. This chart, reflecting overall investor risk appetite, is critical for NeuroSense. Market optimism allows companies like this to more easily attract capital for research in areas with significant unmet medical need.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612878434 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NeuroSense Therapeutics
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects research funding, not commercial revenue. It illustrates the investment in drug discovery for some of the most devastating diseases.
Sales of companies in the market segment - Neuro
NeuroSense Therapeutics Ltd. is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). Its activities are segmented into various development programs. This chart depicts the financial flows associated with its lead candidate, showing its clinical progress.
Overall market sales
NeuroSense Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its success depends entirely on the results of clinical trials. The company is working to solve one of the most complex and tragic problems in medicine, where the need for new treatments is enormous.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NeuroSense Therapeutics
NeuroSense Therapeutics is a clinical-stage biotechnology company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its future sales projections are a bet on the success of its clinical program for this devastating disease.
%20sales%20of%20the%20company%20NeuroSense%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NeuroSense-Therapeutics&v=1772612878566 "Schedule of future (projected) sales of the company NeuroSense Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects expectations for the entire neuroscience sector. It helps assess the progress analysts are predicting in treating rare and severe brain diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772612878640 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases. Funding for such long-term research depends on market sentiment. This chart of overall sales forecasts reflects economic confidence, which influences investor willingness to invest in the risky biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612878777 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NeuroSense Therapeutics
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects its financial position, where high R&D expenditures are an investment in the development of life-saving drugs.
Market segment marginality - Neuro
NeuroSense Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Effectiveness in this complex field lies in the ability to advance risky but potentially breakthrough programs while managing capital prudently.
Market marginality as a whole
NeuroSense Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows the profitability of mature businesses, while NRSN's value is determined by the potential of its research to offer hope to patients with incurable diseases.
Employees in the company, segment and market as a whole
Number of employees in the company NeuroSense Therapeutics
NeuroSense Therapeutics is a biotech company developing a treatment for amyotrophic lateral sclerosis (ALS). This graph shows its team of scientists and clinicians. The growth of this team is an indicator of progress in clinical trials for this much-needed drug.
Share of the company's employees NeuroSense Therapeutics within the market segment - Neuro
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This is one of the most challenging areas in medicine. This figure reflects the company's commitment to combating these devastating diseases.
Number of employees in the market segment - Neuro
NeuroSense Therapeutics is developing combination therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows employment in the neuroscience sector. The growing number of researchers in this field demonstrates the urgent need for effective treatments for these devastating diseases.
Number of employees in the market as a whole
NeuroSense Therapeutics develops drugs to treat neurodegenerative diseases. Its future depends on the results of clinical trials. This chart shows overall activity, but for NeuroSense, one successful trial report could change everything, attracting significant investment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics Ltd. is an Israeli company developing drugs to treat neurodegenerative diseases. This chart likely shows a very high market capitalization per employee. The market doesn't value headcount, but rather scientific potential and the potential for developing a cure for diseases like amyotrophic lateral sclerosis.
%20of%20the%20company%20NeuroSense%20Therapeutics%20(NRSN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NeuroSense-Therapeutics-NRSN&v=1772612879168 "Chart of market capitalization per employee (in thousands of dollars) of the company NeuroSense Therapeutics (NRSN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
NeuroSense Therapeutics is a clinical-stage company developing drugs for the treatment of neurodegenerative diseases such as ALS. In this complex field of biopharma, cost per employee is the market's assessment of scientific potential and the prospects for clinical success. It is an indicator of the value of their research team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772612879218 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
NeuroSense Therapeutics is a clinical-stage biotech company developing a drug to treat amyotrophic lateral sclerosis (ALS). The chart shows the high speculative market valuation of the team working on a treatment for this devastating disease.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612879290 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing a combination drug for the treatment of amyotrophic lateral sclerosis (ALS). It is an R&D company. This negative graph shows how much capital the company is burning through per scientist and doctor in the desperate race to develop an effective treatment for this deadly neurodegenerative disease.
%20Chart%20NeuroSense%20Therapeutics%20(NRSN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NeuroSense-Therapeutics-NRSN&v=1772612879333 "Company Profit Per Employee (in thousands of dollars) Chart NeuroSense Therapeutics (NRSN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
NeuroSense Therapeutics is a biopharmaceutical company developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Success depends on the scientific team and clinical trial results. This chart shows the value their specialists create, serving as a benchmark for their effectiveness in the complex field of neuroscience.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772612879419 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
NeuroSense Therapeutics (NRSN) is a biotech company developing drugs to treat neurodegenerative diseases (such as ALS). It is a clinical-stage R&D company. Negative profit per employee is the norm. The graph shows the "cost" of a team of scientists working on this complex problem.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612879550 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases. Its revenue is currently unknown. This graph is a bet on the future success of its clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NeuroSense-Therapeutics-NRSN&v=1772612879692 "Sales chart per company employee NeuroSense Therapeutics (NRSN)")
Sales per employee in the market segment - Neuro
NeuroSense Therapeutics is a biopharmaceutical company developing a combination drug for the treatment of ALS (Lou Gehrig's disease). This is an extremely complex field. This chart compares revenue per employee (R&D) to the industry average. This reflects how productive their scientific approach is in developing a cure.
Sales per employee for the market as a whole
NeuroSense Therapeutics (NRSN) is an Israeli biotech company developing a combination drug for the treatment of ALS (Lou Gehrig's disease). It is a clinical-stage R&D company with no commercial sales revenue. This graph would show $0, which is typical for a biotech company at this stage.
Short shares by company, segment and market as a whole
Shares shorted by company NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics (NRSN) is an Israeli company developing a drug to treat ALS (Lou Gehrig's disease). It is one of the most terrifying and difficult-to-treat diseases. This chart shows the number of investors who are skeptical about NRSN's chances of succeeding where all others have failed.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NeuroSense-Therapeutics-NRSN&v=1772612879817 "Short Shares Chart for the Company NeuroSense Therapeutics (NRSN)")
Shares shorted by market segment - Neuro
NeuroSense Therapeutics is an Israeli biotech company developing a combination drug for the treatment of ALS (amyotrophic lateral sclerosis), a fatal neurodegenerative disease. This chart shows the odds against the "neurological biotech" sector. ALS is a "drug graveyard," and investors are extremely skeptical of new treatments.
Shares shorted by the overall market
NeuroSense is a biotech company searching for a cure for ALS (Lou Gehrig's disease). This is an extremely complex area of R&D. This chart illustrates the overall market pessimism. When investors are fearful, they are unwilling to fund long-term scientific endeavors with a high risk of failure. Capital becomes scarce for companies like NeuroSense.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics is an Israeli biotech developing a drug to treat ALS (Lou Gehrig's disease), one of the most challenging targets in medicine. This oscillator measures investor "fever": any hint of success in trials can trigger "overheating" (above 70), while failure can lead to deep "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NeuroSense-Therapeutics-NRSN&v=1772612879947 "RSI 14 indicator chart for the company's stock NeuroSense Therapeutics (NRSN)")
RSI 14 Market Segment - Neuro
NeuroSense Therapeutics is an Israeli biopharmaceutical company developing a combination drug for the treatment of ALS (Lou Gehrig's disease) and other neurodegenerative diseases. This chart shows the overall momentum in the neuro biotech segment. It helps distinguish the reaction to the NRSN news from general euphoria or panic across this complex industry.
RSI 14 for the overall market
NeuroSense (NRSN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NRSN (NeuroSense Therapeutics)
NeuroSense (NRSN) is a biotech company developing a combination drug (PrimeC) for the treatment of neurodegenerative diseases, with a primary focus on ALS (amyotrophic lateral sclerosis). This chart shows the speculative average price target from analysts, based on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NRSN-NeuroSense-Therapeutics&v=1772612880157 "A chart showing analyst consensus forecasts for the expected stock price. NRSN (NeuroSense Therapeutics)")
The difference between the consensus estimate and the actual stock price NRSN (NeuroSense Therapeutics)
NeuroSense is an Israeli biotech company developing a combination drug for the treatment of ALS (Lou Gehrig's disease) and other neurodegenerative diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this complex R&D program.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NRSN-NeuroSense-Therapeutics&v=1772612880176 "A chart showing the difference between the consensus forecast and the actual stock price. NRSN (NeuroSense Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
NeuroSense (NRSN) is an Israeli biotech company developing a combination drug for the treatment of ALS (Lou Gehrig's disease), one of the most devastating neurodegenerative diseases. This chart shows general expectations for the neuroscience sector, reflecting whether experts believe a breakthrough in ALS treatment is possible.
Analysts' consensus forecast for the overall market share price
NeuroSense Therapeutics (NRSN) is an Israeli biopharmaceutical company attacking ALS (Lou Gehrig's disease). They are developing a combination drug that should slow the progression of this deadly disease. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D projects in one of the most complex areas of neuroscience.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NeuroSense Therapeutics
NeuroSense Therapeutics is an Israeli clinical-stage biotech company focused on one of the most dreaded diseases: ALS (amyotrophic lateral sclerosis). Their drug is a combination of existing drugs designed to halt neurodegeneration. This graph is a clear indicator of faith in their R&D. Its dynamics are all or nothing, depending entirely on their clinical data.
AKIMA Market Segment Index - Neuro
NeuroSense Therapeutics (NRSN) is an Israeli biopharmaceutical company specializing in the treatment of neurodegenerative diseases, particularly ALS (Lou Gehrig's disease). They are developing a combination therapy, PrimeC. The chart shows the segment average index, helping investors assess how NRSN's risks in this complex field compare to the sector average.
The AKIM Index for the overall market
NeuroSense Therapeutics is a biotech company developing combination therapies for the treatment of ALS (amyotrophic lateral sclerosis) and other neurodegenerations. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story compares to overall economic trends.
